Corporate pension plan funding levels showed little change

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
112
Corporate pension plan funding levels showed little change in 2016, Willis Towers Watson analysis finds

ARLINGTON, Va., Jan. 03, 2017 (GLOBE NEWSWIRE) -- In what turned out to be a seesaw year, the pension funded status of the nation’s largest corporate plan sponsors remained essentially unchanged at the end of 2016 compared with the end of 2015, as lower interest rates, which push up liabilities, negated positive stock market returns, according to a new analysis by Willis Towers Watson (NASDAQ: WLTW ), a leading global advisory, broking and solutions company. 

The Willis Towers Watson analysis examined pension plan data for the 410 Fortune 1000 companies that sponsor U.S. defined benefit pension plans and have a December fiscal-year-end date. Results indicate that the aggregate pension funded status is estimated to be 80% at the end of 2016, compared with 81% at the end of 2015. The analysis also found that the pension deficit is projected to have increased $17 billion to $325 billion at the end of 2016, compared to a $308 billion deficit at the end of 2015.

Fortune 1000 aggregate pension plan funding levels
Year 2001   2002   2003   2004   2005   2006  2007   2008   2009   2010   2011   2012   2013   2014   2015   2016*
Aggregate level 101 % 82 % 89 % 90 % 91 % 99 % 106 % 77 % 81 % 84 % 78 % 77 % 89 % 81 % 81 % 80 %

*Estimated

“Rising interest rates and the stock market rally following the recent presidential election helped turn around what, to that point, had been a tough year for the funded status of corporate pension plans,” said Alan Glickstein, a senior retirement consultant at Willis Towers Watson. “Before the election, pension plans were on track to decline by roughly five percentage points, as interest rates had dropped considerably over the first half of the year. However, an end-of-year jump in interest rates, coupled with strong equity returns in the stock market resulted in a rebound in funded status.”

According to the analysis, pension plan assets inched higher in 2016, from $1.30 trillion at the end of 2015 to an estimated $1.31 trillion at the end of last year. Overall investment returns are estimated to have averaged 6.7% in 2016, although returns varied significantly by asset class. Domestic large-capitalization equities returned 12.0%, while domestic small-/mid-capitalization equities earned 17.6%. Aggregate bonds provided a 2.7% return; long corporate and long government bonds, typically used in liability-driven investing strategies, earned 10.2% and 1.3%, respectively.

The Willis Towers Watson analysis estimates that companies contributed $35 billion to their pension plans in 2016. These contributions were significantly higher than the $31 billion employers contributed to their plans in 2015 but still well below contribution levels from previous years. Employer contributions have been declining steadily for the last several years partly due to legislated funding relief.

Total pension obligations moved up from $1.61 trillion to $1.64 trillion. A 28-basis-point decline in discount rates pushed liability values up 3.4%, while a change in anticipated mortality improvements dropped liabilities 0.9%.

“Plan sponsors will want to keep a close watch on two key developments as we move into the new year — whether interest rates continue to rise and President-elect Donald Trump’s promise for tax reform becomes reality. Both of these developments will certainly motivate employers to evaluate their pension de-risking strategies and consider implementing lump sum buyouts or annuity purchases,” said Dave Suchsland, a senior retirement consultant at Willis Towers Watson.

About the analysis Willis Towers Watson analyzed 410 Fortune 1000 companies with December fiscal-year-end dates for which complete data were available. The 2016 figures are estimates of U.S. plan assets and liabilities. The earlier figures are actual. Actual year-end 2016 results will be publicly available in a few months.

About Willis Towers Watson

Willis Towers Watson (NASDAQ: WLTW ) is a leading global advisory, broking and solutions company that helps clients around the world turn risk into a path for growth. With roots dating to 1828, Willis Towers Watson has 39,000 employees in more than 120 countries. We design and deliver solutions that manage risk, optimize benefits, cultivate talent, and expand the power of capital to protect and strengthen institutions and individuals. Our unique perspective allows us to see the critical intersections between talent, assets and ideas — the dynamic formula that drives business performance. Together, we unlock potential. Learn more at willistowerswatson.com.

Media contact Ed Emerman: +1 609 275 5162 eemerman@eaglepr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 6

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading

Top 5 Most Recently Viewed Articles

PMGC Capital's Strategic Investment in Alaunos Therapeutics

Updated Category News Views 171

PMGC Capital LLC Plans to File Schedule 13D on Alaunos PMGC Capital LLC, a fully owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has made a significant move in the financial landscape by announcing its intention to file a Schedule 13D with the U.S. Securities and Exchange Commission (SEC). This filing will disclose its beneficial ownership in Alaunos Therapeutics,...

Continue Reading
Black Diamond Therapeutics: Pivotal Developments Ahead

Updated Category News Views 97

Black Diamond Therapeutics Continues to Make Strides Recently, H.C. Wainwright confirmed a Buy rating on Black Diamond Therapeutics (NASDAQ: BDTX) shares, projecting a price target of $11.00. This positive outlook follows the company's major restructuring efforts aimed at advancing BDTX-1535, its leading drug candidate, into pivotal trials. This move is expected to not...

Continue Reading
Eureka Acquisition Corp Announces New Meeting Date and Deadlines

Updated Category News Views 187

Eureka Acquisition Corp's Important Announcement New York — Eureka Acquisition Corp (NASDAQ: EURK), a special purpose acquisition company, has recently made significant announcements regarding the schedule of its extraordinary general meeting. Originally set for June 20, it will now take place on June 25, providing shareholders with extra time for participation. Details...

Continue Reading
Diamedica Therapeutics Hits New Heights with $6.41 Stock Value

Updated Category News Views 118

Diamedica Therapeutics Inc. Achieves 52-Week High Diamedica Therapeutics Inc. (NASDAQ: DMAC) is making headlines as its stock has recently hit a remarkable 52-week high of $6.41. This impressive milestone comes amid a significant growth phase for the company, which is currently valued at around $230 million. The steep rise in the stock price over the past year indicates a...

Continue Reading
J.P. Morgan's Projections for 2025: Capital Market Insights

Updated Category News Views 6083

J.P. Morgan's Capital Market Assumptions for 2025 J.P. Morgan Asset Management has recently unveiled its 2025 Long-Term Capital Market Assumptions (LTCMAs), providing valuable insights into the anticipated returns and risks across various asset classes for the next decade. These projections serve as a compass for investment strategies, targeting institutional and...

Continue Reading